Compare DHIL & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHIL | CRMD |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 509.9M |
| IPO Year | 1996 | 2009 |
| Metric | DHIL | CRMD |
|---|---|---|
| Price | $174.96 | $7.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.20 |
| AVG Volume (30 Days) | 13.8K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | 14.37 | ★ 780.00 |
| EPS | ★ 17.91 | 2.04 |
| Revenue | $145,201,729.00 | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.67 | ★ $3.62 |
| Revenue Growth | 6.69 | ★ 617.03 |
| 52 Week Low | $114.11 | $6.13 |
| 52 Week High | $173.70 | $17.43 |
| Indicator | DHIL | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 70.34 | 66.10 |
| Support Level | $171.71 | $6.14 |
| Resistance Level | N/A | $8.53 |
| Average True Range (ATR) | 0.65 | 0.25 |
| MACD | 0.16 | 0.07 |
| Stochastic Oscillator | 98.87 | 94.12 |
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.